Tag results:

mesenchymal stem cells

miR-100-5p in Human Umbilical Cord Mesenchymal Stem Cell–Derived Exosomes Mediates Eosinophilic Inflammation to Alleviate Atherosclerosis via the FZD5/Wnt/β-Catenin Pathway

[Acta Biochimica et Biophysica Sinica] Exosome marker protein levels were increased in the exosomes derived from human umbilical cord MSCs (hUMSC-Ex) compared with those in hUMSC suspension, indicating that exosomes were successfully isolated from hUMSCs.

The Tissue Origin of Human Mesenchymal Stem Cells Dictates Their Therapeutic Efficacy on Glucose and Lipid Metabolic Disorders in Type II Diabetic Mice

[Stem Cell Research & Therapy] Scientists report a comprehensive comparison of human MSCs derived from umbilical cord Wharton’s jelly (UC-MSCs), dental pulp, and adipose tissue on the treatment of glucose and lipid metabolic disorders in type II diabetic mice.

Application of Mesenchymal Stem Cell Sheet to Treatment of Ischemic Heart Disease

[Stem Cell Research & Therapy] Umbilical cord (UC)-MSCs have few human leukocyte antigen-II and major histocompatibility complex class I molecules, and are easy to isolate and culture, UC-MSC sheets have been proposed as a candidate for clinical applications to ischemic heart disease.

Cartilage from Human-Induced Pluripotent Stem Cells: Comparison with Neo-Cartilage From Chondrocytes and Bone Marrow Mesenchymal Stromal Cells

[Cell and Tissue Research] Scientists explored whether human-induced pluripotent stem cells could represent unlimited cell sources for neo-cartilage comparable to human primary articular chondrocytes or human bone marrow-derived MSCs.

Stem Cell Therapy Company Amniotics Raises SEK 60 Million before Deduction of Transaction Costs, in First North IPO to Advance Lead Candidate PulmoStemâ„¢ Into...

[Amniotics AB] Amniotics AB has raised SEK60 million through its recent listing on Nasdaq. The funds will now be deployed to advance the company’s preclinical portfolio of cell therapy candidates based on MSC from amniotic fluid. Lead candidate PulmoStem™, a first-in-class treatment for pulmonary disease is scheduled to enter the clinic.

A SNAI2-PEAK1-INHBA Stromal Axis Drives Progression and Lapatinib Resistance in HER2-Positive Breast Cancer by Supporting Subpopulations of Tumor Cells Positive for Antiapoptotic and Stress...

[Oncogene] Mesenchymal stem cells and cancer-associated fibroblasts expressed high PEAK1 protein levels and potentiated tumorigenesis, lapatinib resistance and metastasis of HER2-positive breast cancer cells in a PEAK1-dependent manner.

Popular